Publications

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

 124
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

Next Article

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

Sertm2 is a conserved micropeptide that promotes GDNF-mediated motor neuron subtype specification

Sertm2 is a conserved micropeptide that promotes GDNF-m...

 112

Human hippocampal CA3 uses specific functional connectivity rules for efficient associative memory

Human hippocampal CA3 uses specific functional connecti...

 119

Reinventing type 2 immunity in cancer

Reinventing type 2 immunity in cancer

 124